Introduction: Why Your Breast Cancer Subtype Changes Everything

When a patient hears the words "you have breast cancer," the diagnosis can feel like a single, overwhelming verdict. But breast cancer is not one disease, it is a family of diseases, each with its own biology, behaviour, and best treatment approach.

Two of the most commonly misunderstood subtypes are HER2-positive breast cancer and Triple Negative Breast Cancer (TNBC). As a breast cancer specialist doctor in Delhi with over 20 years of oncology experience, one of the most important things I tell every patient is this: knowing your subtype is as important as knowing your diagnosis.

In this article, I will break down exactly what these two subtypes mean, how they differ, and why treatment decisions must be tailored to the individual, not just the cancer.

What Is HER2-Positive Breast Cancer?

HER2 stands for Human Epidermal Growth Factor Receptor 2, a protein that, in normal amounts, helps breast cells grow and repair. When a breast cancer cell produces too much of this protein (a process called HER2 overexpression), it causes cancer cells to multiply much faster than normal.

Key facts about HER2-positive breast cancer:

• Accounts for approximately 15–20% of all breast cancers
• Tends to grow faster than hormone receptor-positive cancers
• Was once considered high-risk, but targeted therapies have dramatically improved outcomes
• Diagnosed through IHC (Immunohistochemistry) and FISH (Fluorescence In Situ Hybridisation) tests on a biopsy sample

HER2-positive breast cancer can also be hormone receptor-positive (ER+ or PR+) at the same time, which further influences the treatment plan.

What Is Triple Negative Breast Cancer (TNBC)?

Triple Negative Breast Cancer earns its name because it tests negative for three receptors, estrogen receptor (ER), progesterone receptor (PR), and HER2. This is clinically significant because most targeted breast cancer treatments work by blocking one of these three receptors. When all three are absent, those treatments simply don't apply.

Key facts about TNBC:

• Represents about 10–15% of all breast cancers
• More common in younger women and women of South Asian and African descent
• Tends to be more aggressive and has a higher rate of early recurrence
• Currently treated primarily with chemotherapy and immunotherapy
• A genetic mutation (BRCA1/BRCA2) is found in a significant subset of TNBC patients

TNBC is often the subtype that patients fear the most, and while it does present real challenges, modern treatment protocols have significantly improved survival rates, particularly when caught early.

HER2-Positive vs. Triple Negative Breast Cancer: Key Differences

Treatment for HER2-Positive Breast Cancer

The arrival of targeted therapy has transformed HER2-positive breast cancer from one of the most feared subtypes to one of the most treatable. Here is how it is typically managed:

1. Targeted Therapy (the game-changer)

Drugs like Trastuzumab (Herceptin) and Pertuzumab specifically target the HER2 protein, essentially blocking the signal that tells cancer cells to grow. These are given alongside chemotherapy and have dramatically improved survival outcomes.

2. Chemotherapy

A course of chemotherapy is typically given either before surgery (neoadjuvant) to shrink the tumour, or after surgery (adjuvant) to eliminate any remaining cancer cells.

3. Surgery

Depending on tumour size and spread, surgery may involve a lumpectomy (removal of the tumour) or mastectomy (removal of the breast). The surgical approach is always discussed in the context of the patient's overall health, preferences, and cancer stage.

4. Hormone Therapy (if also ER/PR+)

If the tumour is also hormone receptor-positive, drugs like Tamoxifen or Aromatase Inhibitors are added to the treatment plan after chemotherapy.

5. Newer Agents

More recently, drugs like Trastuzumab Deruxtecan (T-DXd), an antibody-drug conjugate, have shown remarkable results in HER2-positive metastatic breast cancer, offering new hope for advanced-stage patients.

Treatment for Triple Negative Breast Cancer (TNBC)

Because TNBC lacks the three common receptors that most targeted drugs rely on, treatment has historically leaned heavily on chemotherapy. However, the landscape is rapidly changing.

1. Chemotherapy (primary treatment)

TNBC tends to respond well to chemotherapy initially, which is why it is often the first-line treatment. Neoadjuvant chemotherapy (given before surgery) is commonly used to assess how the tumour responds.

2. Immunotherapy

One of the most exciting recent developments in TNBC treatment is immunotherapy, particularly with Pembrolizumab (Keytruda). It is now approved for use in certain early-stage and metastatic TNBC patients who test positive for the PD-L1 protein. Immunotherapy works by empowering the body's immune system to recognise and attack cancer cells.

3. PARP Inhibitors

For patients with BRCA1 or BRCA2 mutations, PARP inhibitors such as Olaparib and Talazoparib have proven effective. These drugs exploit a specific DNA repair weakness in BRCA-mutant cancer cells.

4. Surgery and Radiation

Like HER2-positive cancer, surgery and radiation therapy remain important components of TNBC treatment, particularly in localised disease.

5. Antibody-Drug Conjugates

Sacituzumab Govitecan is a newer antibody-drug conjugate approved for metastatic TNBC, offering meaningful benefit for patients who have progressed on prior treatments.

Which Type Is More Aggressive? Understanding Prognosis

This is one of the most common questions I receive as a breast cancer specialist doctor in Delhi, and the honest answer is: it depends on the stage, the patient, and access to the right treatment.

Generally speaking, TNBC grows faster and has a higher risk of spreading in the first 3–5 years after diagnosis. However, it also tends to respond dramatically to chemotherapy when it does respond, a phenomenon oncologists call "pathological complete response."

HER2-positive cancer, while also fast-growing, now has excellent prognosis data thanks to targeted therapies. A patient with early-stage HER2-positive breast cancer treated with standard protocols today has a very strong chance of long-term survival.

The single most important factor in prognosis for both subtypes is early detection. A Stage I HER2-positive or TNBC tumour treated promptly carries a far better outlook than a Stage III tumour discovered late.

Why Early Diagnosis Is the Most Powerful Tool

As a medical oncologist in Delhi NCR, I cannot overstate the importance of early screening. Many patients come to me after weeks or months of ignoring a lump or dismissing unusual symptoms. By the time they arrive, a Stage I problem has become a Stage III challenge.

Here is what every woman should do:

• Monthly self-examination - Check for lumps, changes in breast shape, nipple changes, or skin dimpling
• Annual clinical breast exam - After age 30, get examined by a qualified breast specialist
• Mammography - Women above 40 should have annual mammograms; women with family history should start earlier
• Genetic counselling - If you have a family history of breast or ovarian cancer, BRCA testing can be life-saving
• Don't delay - If you notice anything unusual, see a breast cancer specialist doctor in Delhi immediately. Waiting weeks is not worth the risk.

Expert Perspective: Dr. Kumardeep Dutta Choudhury on Personalised Cancer Care

At my practice at Max Hospital, New Delhi, I see patients with both HER2-positive and Triple Negative breast cancer regularly. What I tell every patient is the same: your cancer is unique, and so is your treatment plan.

We do not use a one-size-fits-all protocol. Every patient undergoes comprehensive molecular profiling, which means we test not just for HER2, ER, and PR, but also for genetic mutations, tumour grade, and other biomarkers that help us select the most effective, and least toxic, treatment path.

The best outcomes I have witnessed in my 20+ years as a medical oncologist in Delhi NCR have come from patients who arrived early, stayed consistent with their treatment, and had the support of a multidisciplinary team involving oncologists, surgeons, radiologists, and counsellors working together.

If you or a loved one has received a breast cancer diagnosis, I urge you not to lose hope, and not to wait. The right information and the right specialist can make all the difference.

FAQs

1. What is the difference between HER2-positive and Triple Negative breast cancer?

Ans: HER2-positive breast cancer overexpresses the HER2 protein and can be treated with targeted therapies like Trastuzumab. Triple Negative Breast Cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, making it harder to treat with targeted drugs, but chemotherapy and immunotherapy are effective options.

2. Is Triple Negative breast cancer curable?

Ans: Yes, particularly when detected at an early stage. Many TNBC patients achieve complete remission with chemotherapy and, where applicable, immunotherapy. The key is early diagnosis and treatment at a specialised cancer centre.

3. Which breast cancer subtype has the best prognosis?

Ans: Hormone receptor-positive (ER+/PR+) breast cancer generally has the best long-term prognosis. However, early-stage HER2-positive cancer also has excellent outcomes due to targeted therapies. TNBC prognosis has improved significantly with modern immunotherapy protocols.

4. Should I get a BRCA gene test if I have Triple Negative breast cancer?

Ans: Yes. BRCA1 and BRCA2 mutations are found in a notable proportion of TNBC patients. A positive BRCA result opens the door to PARP inhibitor therapy and also has important implications for other family members.

5. How do I find the best breast cancer specialist doctor in Delhi?

Ans: Look for an oncologist with specific experience in breast cancer, access to molecular profiling and multidisciplinary tumour boards, and a track record of managing both HER2-positive and TNBC cases. Dr. Kumardeep Dutta Choudhury at Max Hospital, New Delhi, offers personalised, evidence-based breast cancer care for patients across Delhi NCR.

Conclusion: The Right Diagnosis, the Right Doctor, the Right Time

HER2-positive and Triple Negative breast cancer are two very different diseases requiring two very different treatment approaches. Understanding your specific subtype is not just medically important, it is empowering. It allows you and your oncologist to make informed, targeted decisions that give you the best possible chance of recovery. If you are looking for an experienced breast cancer specialist doctor in Delhi, or seeking a second opinion on a recent diagnosis, I welcome you to reach out.